Adverum Financial Statements From 2010 to 2023

ADVM Stock

USD 0.76 0.01 1.33%

Adverum Biotechnologies financial statements provide useful quarterly and yearly information to potential Adverum Biotechnologies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adverum Biotechnologies financial statements helps investors assess Adverum Biotechnologies' valuation, profitability, and current liquidity needs.

There are over ninety-five available fundamental signals for Adverum Biotechnologies, which can be analyzed over time and compared to other ratios. Make sure you validate Adverum Biotechnologies' prevailing fundamentals against the trend between 2010 and 2023 to make sure the company can sustain itself down the road.

Adverum Biotechnologies Average Assets are very stable at the moment as compared to the past year. Adverum Biotechnologies reported last year Average Assets of 551.43 Million. As of 26th of March 2023, Enterprise Value is likely to grow to about 377.3 M, while Revenue Per Employee is likely to drop about 38.4 K.

Check Adverum Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adverum main balance sheet or income statement drivers, such as Gross Profit of 9.3 M, Interest Expense of 30 K or Operating Expenses of 190.6 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0997, PPandE Turnover of 0.29 or Receivables Turnover of 2.56. Adverum financial statements analysis is a perfect complement when working with Adverum Biotechnologies Valuation or Volatility modules. It can also supplement Adverum Biotechnologies' financial leverage analysis and stock options assessment as well as various Adverum Biotechnologies Technical models . Check out the analysis of Adverum Biotechnologies Correlation against competitors. To learn how to invest in Adverum Stock please use our How to Invest in Adverum Biotechnologies guide.

Adverum Biotechnologies Revenues

9.31 Million

Adverum Biotechnologies Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Tax Liabilities

1.1 M

1.2 M

Down

Slightly volatile

Trade and Non Trade Receivables

8 M

7.4 M

3.5 M

Slightly volatile

Property Plant and Equipment Net

147.7 M

136.9 M

36.6 M

Slightly volatile

Trade and Non Trade Payables

1.8 M

1.6 M

1.5 M

Slightly volatile

Liabilities Non Current

126.8 M

117.6 M

31 M

Slightly volatile

Current Liabilities

26.5 M

24.5 M

11.4 M

Slightly volatile

Total Liabilities

153.3 M

142.1 M

42.4 M

Slightly volatile

Investments Current

255.3 M

311.6 M

130.1 M

Slightly volatile

Investments

255.3 M

311.6 M

130.1 M

Slightly volatile

Goodwill and Intangible Assets

4.5 M

4.9 M

Down

Slightly volatile

Shareholders Equity USD

302.3 M

363.6 M

184 M

Slightly volatile

Shareholders Equity

302.3 M

363.6 M

184 M

Slightly volatile

Deferred Revenue

8.5 M

8.2 M

7.4 M

Pretty Stable

Total Debt USD

125.5 M

116.3 M

40.6 M

Slightly volatile

Debt Non Current

125.5 M

116.3 M

40.6 M

Slightly volatile

Total Debt

125.5 M

116.3 M

40.6 M

Slightly volatile

Cash and Equivalents USD

33.9 M

33 M

76.1 M

Very volatile

Cash and Equivalents

33.9 M

33 M

76.1 M

Very volatile

Assets Non Current

152.1 M

141 M

38.4 M

Slightly volatile

Current Assets

306.5 M

364.7 M

189.3 M

Slightly volatile

Total Assets

545.6 M

505.7 M

233.9 M

Slightly volatile

Accumulated Other Comprehensive Income

(659.5 K)

(642.6 K)

(337.2 K)

Down

Slightly volatile

Accounts Payable

1.3 M

1.2 M

1.4 M

Slightly volatile

Receivables

5.5 M

5.1 M

2.9 M

Slightly volatile

Adverum Biotechnologies Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Income Tax Expense

1.4 M

1.3 M

(137.1 K)

Slightly volatile

Weighted Average Shares Diluted

121.6 M

112.7 M

48.2 M

Slightly volatile

Weighted Average Shares

121.6 M

112.7 M

48.2 M

Slightly volatile

Selling General and Administrative Expense

80 M

74.1 M

28.2 M

Slightly volatile

Research and Development Expense

110.7 M

102.6 M

41.9 M

Slightly volatile

Revenues USD

9.3 M

8.6 M

3 M

Slightly volatile

Revenues

9.3 M

8.6 M

3 M

Slightly volatile

Preferred Dividends Income Statement Impact

2.9 M

3.2 M

Down

Slightly volatile

Operating Expenses

190.6 M

176.7 M

75 M

Slightly volatile

Interest Expense

30 K

20.7 K

20.8 K

Very volatile

Gross Profit

9.3 M

8.6 M

3 M

Slightly volatile

Adverum Biotechnologies Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Share Based Compensation

31.3 M

29 M

12.2 M

Slightly volatile

Effect of Exchange Rate Changes on Cash

(714.9 K)

(696.6 K)

(387.5 K)

Down

Slightly volatile

Net Cash Flow Investment Acquisitions and Disposals

91.1 M

84.4 M

(20.9 M)

Pretty Stable

Net Cash Flow from Investing

76.4 M

70.8 M

(12.8 M)

Very volatile

Net Cash Flow from Financing

2.8 M

56.3 M

Pretty Stable

Issuance Repayment of Debt Securities

(221.7 K)

(216 K)

300 K

Down

Slightly volatile

Issuance Purchase of Equity Shares

3.1 M

3 M

86.5 M

Down

Pretty Stable

Net Cash Flow Business Acquisitions and Disposals

3.1 M

3.4 M

Down

Slightly volatile

Net Cash Flow or Change in Cash and Cash Equivalents

(24.7 M)

(24.1 M)

(1 M)

Down

Pretty Stable

Depreciation Amortization and Accretion

5.8 M

5.3 M

2 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Tangible Assets Book Value per Share

5.76

5.16

4.5541

Slightly volatile

Sales per Share

0.0584

0.0693

0.0492

Pretty Stable

Return on Invested Capital

(0.27)

(0.26)

9.9728

Down

Pretty Stable

Return on Average Equity

(0.37)

(0.36)

0.0083

Down

Slightly volatile

Price to Sales Ratio

27.15

26.46

638

Down

Slightly volatile

Price to Book Value

0.51

0.49

3.7275

Down

Slightly volatile

Gross Margin

0.89

0.9

0.9853

Down

Slightly volatile

Enterprise Value over EBITDA

(2.23)

(2.06)

(16.905)

Slightly volatile

Enterprise Value over EBIT

(2.48)

(2.3)

(16.7699)

Slightly volatile

Debt to Equity Ratio

0.48

0.45

0.052

Slightly volatile

Current Ratio

19.15

17.11

15.1767

Slightly volatile

Book Value per Share

4.51

3.71

3.5974

Slightly volatile

Asset Turnover

0.0148

0.0144

0.1936

Down

Slightly volatile

Total Assets Per Share

3.95

4.02

3.6976

Slightly volatile

Receivables Turnover

2.56

2.5

32.08

Down

Slightly volatile

PPandE Turnover

0.29

0.28

4.0826

Down

Slightly volatile

Cash and Equivalents Turnover

0.18

0.3494

Down

Slightly volatile

Accounts Payable Turnover

3.47

3.22

1.7168

Slightly volatile

Accrued Expenses Turnover

0.46

0.43

0.3064

Slightly volatile

Long Term Debt to Equity

0.0997

0.0695

0.1359

Down

Slightly volatile

Quick Ratio

20.85

16.77

22.0761

Down

Slightly volatile

Net Current Assets as percentage of Total Assets

54.63

60.55

29.9285

Slightly volatile

Revenue to Assets

0.0201

0.0196

0.0561

Down

Slightly volatile

Adverum Biotechnologies Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Working Capital

287.4 M

340.2 M

178.4 M

Slightly volatile

Tangible Asset Value

545.6 M

505.7 M

233.2 M

Slightly volatile

Market Capitalization

159.6 M

155.5 M

648.4 M

Down

Slightly volatile

Invested Capital Average

627.7 M

581.7 M

175.8 M

Slightly volatile

Invested Capital

599.1 M

555.2 M

172.7 M

Slightly volatile

Enterprise Value

377.3 M

290.5 M

568.7 M

Down

Slightly volatile

Average Equity

342 M

418.6 M

188.2 M

Slightly volatile

Average Assets

595 M

551.4 M

238 M

Slightly volatile

Revenue Per Employee

38.4 K

45.9 K

30.3 K

Pretty Stable

Adverum Fundamental Market Drivers

Cash And Short Term Investments

305.2 M

Adverum Upcoming Events

	4th of April 2023 Upcoming Quarterly Report	View
	11th of May 2023 Next Financial Report	View
	31st of December 2022 Next Fiscal Quarter End	View
	4th of April 2023 Next Fiscal Year End	View
	30th of September 2022 Last Quarter Report	View
	31st of December 2021 Last Financial Announcement	View

About Adverum Biotechnologies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Adverum Biotechnologies income statement, its balance sheet, and the statement of cash flows. Adverum Biotechnologies investors use historical funamental indicators, such as Adverum Biotechnologies's revenue or net income, to determine how well the company is positioned to perform in the future. Although Adverum Biotechnologies investors may use each financial statement separately, they are all related. The changes in Adverum Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adverum Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adverum Biotechnologies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adverum Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for 2023
Deferred Revenue	8.2 M	8.5 M
Revenues	8.6 M	9.3 M
Revenue to Assets	0.0196	0.0201
Revenue Per Employee	45.9 K	38.4 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in Adverum Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes

All Next

Launch Module

Pair Trading with Adverum Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adverum Biotechnologies

	+	0.61	ARAV	Aravive		Fiscal Quarter End 31st of March 2023	Pair Corr
	+	0.85	ARDX	Ardelyx		Fiscal Quarter End 31st of March 2023	Pair Corr

Moving against Adverum Biotechnologies

-	0.8	BNTX	BioNTech SE	Earnings Call Tomorrow	Pair Corr
-	0.78	JNJ	Johnson Johnson	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.73	ACRX	AcelRx Pharmaceuticals	Earnings Call This Week	Pair Corr
-	0.73	MRNA	Moderna	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.71	CMRX	Chimerix	Fiscal Quarter End 31st of March 2023	Pair Corr

The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.

The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Check out the analysis of Adverum Biotechnologies Correlation against competitors. To learn how to invest in Adverum Stock please use our How to Invest in Adverum Biotechnologies guide. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for analysis

When running Adverum Biotechnologies price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.

	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Focused Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Bond Directory Find actively traded corporate debentures issued by US companies
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.

Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.57)

Quarterly Revenue Growth

(0.70)

Return On Assets

(0.23)

Return On Equity

(0.56)

The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adverum Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

Adverum Financial Statements From 2010 to 2023

Adverum Biotechnologies Revenues

9.31 Million

Adverum Biotechnologies Balance Sheet

Adverum Biotechnologies Income Statement

Adverum Biotechnologies Cash Flow Statement

Financial Ratios

Adverum Biotechnologies Valuation Data

Adverum Fundamental Market Drivers

Adverum Upcoming Events

About Adverum Biotechnologies Financial Statements

Be your own money manager

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Pair Trading with Adverum Biotechnologies

Moving together with Adverum Biotechnologies

Moving against Adverum Biotechnologies

Complementary Tools for analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY